Pancreatic Cancer Research

ResearcherUniversity of AucklandActive in the last 2 years

Sanjay Pandanaboyana

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3099-2197; OpenAlex author ID A5029425563, A5130753951. Sources: OpenAlex.

Their work

Papers
27 (first author 4, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 4 papers · 2023: 2 papers · 2024: 5 papers · 2025: 3 papers · 2026: 4 papers

Papers 27

  1. Short-Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta-Analysis of Observational Studies. Last author DOI 10.1002/wjs.70347↗
  2. Surgery for Locally Advanced Pancreatic Ductal Adenocarcinoma: Selection of Patients and Surgical Technique. Co-author DOI 10.1159/000550333↗
  3. Futility in adenosquamous pancreatic cancer. Co-author DOI 10.1186/s12957-026-04351-1↗
  4. The role of chemoradiotherapy after induction in locally advanced pancreatic cancer: lessons learnt from CONKO-007. First author DOI 10.21037/jgo-2025-aw-852↗
  5. Relationship between pancreatic cancer resection rate and survival at population level: systematic review. Co-author DOI 10.1093/bjsopen/zraf007↗
  6. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Last author DOI 10.1097/sla.0000000000006272↗
  7. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  8. Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: a systematic review. Last author DOI 10.1016/j.hpb.2024.02.001↗
  9. Pancreatic cancer arising in intraductal papillary mucinous neoplasms (IPMN): emerging data warrants further research. First author DOI 10.1093/bjs/znae238↗
  10. ASO Author Reflections: Response to Chemotherapy Differs between Precursor Epithelial Subtypes of Pancreatic Adenocarcinoma Arising from Intraductal Papillary … Last author DOI 10.1245/s10434-024-15784-x↗
  11. Surgical Complications After Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer: From Benchmarks to Randomized Clinical Trials. Last author DOI 10.1245/s10434-024-16134-7↗
  12. Editorial: Technological innovations and pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1497367↗
  13. Assessing impact, needs and quality-of-life among informal carers of people with pancreatic cancer, a prospective study: the PAN-CARER study protocol. Last author DOI 10.1136/bmjopen-2022-068178↗
  14. Redefining resectability in pancreatic cancer after neoadjuvant therapy: are we any closer? First author DOI 10.21037/hbsn-22-638↗
  15. Systematic review of caregiver burden, unmet needs and quality-of-life among informal caregivers of patients with pancreatic cancer. Co-author DOI 10.1007/s00520-022-07468-7↗
  16. Are older patients less likely to be treated for pancreatic cancer? A systematic review and meta-analysis. Co-author DOI 10.1016/j.canep.2022.102215↗
  17. Patient volume and clinical outcome after pancreatic cancer resection: A contemporary systematic review and meta-analysis. Co-author DOI 10.1016/j.surg.2021.11.029↗
  18. Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence. Last author DOI 10.21037/cco-21-161↗
  19. Impact of pancreatic enzyme replacement therapy on short- and long-term outcomes in advanced pancreatic cancer: meta-analysis of randomized controlled trials. Last author DOI 10.1080/17474124.2021.1884544↗
  20. Margin Accentuation Irreversible Electroporation in Stage III Pancreatic Cancer: A Systematic Review. Last author DOI 10.3390/cancers13133212↗
  21. The Impact of the Depth of Venous Invasion on Survival Following Pancreatoduodenectomy for Pancreatic Cancer: a Meta-analysis of Available Evidence. Last author DOI 10.1007/s12029-019-00248-3↗
  22. Prehabilitation prior to surgery for pancreatic cancer: A systematic review. Last author DOI 10.1016/j.pan.2020.07.411↗
  23. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. Last author DOI 10.3390/jcm9072132↗
  24. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. Last author DOI 10.1111/ans.14764↗
  25. Does revision of resection margins based on frozen section improve overall survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma? A met… First author DOI 10.1016/j.hpb.2017.03.006↗
  26. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. Co-author DOI 10.1111/hpb.12355↗
  27. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancrea… Co-author DOI 10.6092/1590-8577/519↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bathiya Ratnayake · 7 shared papers, 2020–2024 · strength 1.20
  2. Benjamin P. T. Loveday · 5 shared papers, 2019–2026 · strength 1.11
  3. John Albert Windsor · 6 shared papers, 2017–2026 · strength 1.05
  4. Kjetil Søreide · 3 shared papers, 2024–2026 · strength 1.01
  5. Keith John Roberts · 5 shared papers, 2020–2026 · strength 1.00
  6. James E. Lucocq · 2 shared papers, 2024 · strength 0.82
  7. Anubhav Mittal · 2 shared papers, 2026 · strength 0.68
  8. Christos Athanasiou · 1 shared paper, 2026 · strength 0.63
  9. Savio George Barreto · 3 shared papers, 2017–2026 · strength 0.62
  10. Francis P. Robertson · 2 shared papers, 2023–2024 · strength 0.62
  11. Linda Sharp · 3 shared papers, 2022–2023 · strength 0.57
  12. Samir Pathak · 3 shared papers, 2015–2025 · strength 0.54
  13. Andrew Malvern Smith · 2 shared papers, 2015–2024 · strength 0.37
  14. Patrik Larsson · 1 shared paper, 2024 · strength 0.36
  15. Ajith Kumar Siriwardena · 2 shared papers, 2023–2025 · strength 0.34
  16. Mikolaj R. Kowal · 1 shared paper, 2024 · strength 0.31
  17. Elizabeth Lockie · 1 shared paper, 2025 · strength 0.30
  18. John Raymond Zalcberg · 1 shared paper, 2025 · strength 0.30
  19. Jaswinder Singh Samra · 1 shared paper, 2026 · strength 0.29
  20. Vivek Peddakota · 1 shared paper, 2026 · strength 0.29
  21. Nigel Balfour Jamieson · 1 shared paper, 2024 · strength 0.23
  22. Eric Chong · 1 shared paper, 2022 · strength 0.20
  23. Kirsty Logan · 1 shared paper, 2022 · strength 0.20
  24. Cristina Vallejo Bernad · 1 shared paper, 2026 · strength 0.18
  25. Julie Navez · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.